Voyager Therapeutics (VYGR)
3.35
-0.08 (2.33%)
Upcoming Events
Latest Headlines
Voyager gets FDA clearance for first tau gene therapy for Alzheimer's
June 1, 2026 8:01 AM - StreetInsider
Form 8-K Voyager Therapeutics, For: Jun 01
June 1, 2026 8:00 AM - SEC Filing
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
June 1, 2026 8:00 AM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)
May 26, 2026 6:58 AM - StreetInsider
Form 3 Voyager Therapeutics, For: May 08 Filed by: Quinlan Amy
May 18, 2026 4:01 PM - SEC Filing
Form 144 Voyager Therapeutics, Filed by: Jorgensen Nathan D.
May 15, 2026 4:13 PM - SEC Filing
Form SCHEDULE 13G/A Voyager Therapeutics, Filed by: EcoR1 Capital, LLC
May 15, 2026 2:17 PM - SEC Filing
Form SCHEDULE 13G/A Voyager Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:04 AM - SEC Filing
Form 144 Voyager Therapeutics, Filed by: Jorgensen Nathan D.
May 15, 2026 10:35 AM - SEC Filing
Voyager presents positive safety data for Alzheimer's gene therapy VY1706
May 13, 2026 6:02 AM - StreetInsider
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
May 13, 2026 6:01 AM - Globe NewsWire
Voyager Therapeutics (VYGR) Tops Q1 EPS by 6c
May 7, 2026 5:52 PM - StreetInsider
Form 8-K Voyager Therapeutics, For: May 07
May 7, 2026 4:08 PM - SEC Filing
Form 10-Q Voyager Therapeutics, For: Mar 31
May 7, 2026 4:04 PM - SEC Filing
Voyager Reports First Quarter 2026 Financial and Operating Results
May 7, 2026 4:01 PM - Globe NewsWire
Form ARS Voyager Therapeutics, For: Dec 31
April 28, 2026 4:09 PM - SEC Filing
Form DEFA14A Voyager Therapeutics,
April 28, 2026 4:04 PM - SEC Filing
Form DEF 14A Voyager Therapeutics, For: Jun 09
April 28, 2026 4:00 PM - SEC Filing
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
April 27, 2026 4:31 PM - Globe NewsWire
Form 8-K Voyager Therapeutics, For: Apr 15
April 21, 2026 4:06 PM - SEC Filing
Amazon cloud unit launches AI tool to accelerate drug discovery
April 14, 2026 10:35 AM - StreetInsider
Form PRE 14A Voyager Therapeutics, For: Jun 09
April 10, 2026 4:22 PM - SEC Filing
Form 4 Voyager Therapeutics, For: Apr 02 Filed by: Sandrock Alfred
April 3, 2026 5:55 PM - SEC Filing
Form 4 Voyager Therapeutics, For: Apr 01 Filed by: Shiferman Gregory L.
April 3, 2026 5:43 PM - SEC Filing
Form 144 Voyager Therapeutics, Filed by: Sandrock Alfred
April 2, 2026 3:53 PM - SEC Filing
Form SCHEDULE 13G/A Voyager Therapeutics, Filed by: VANGUARD GROUP INC
March 27, 2026 2:17 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)
March 18, 2026 7:55 AM - StreetInsider
Truist Securities Reiterates Buy Rating on Voyager Therapeutics (VYGR): 'evolving into a platform-agnostic, CNS disease focused biotech'
March 16, 2026 9:02 AM - StreetInsider
Full Article List
